Compounding Pharmacies Jump on Shortage Opportunity In 2022, the FDA added Eli Lillys Zepbound and Novo Nordisks Wegovyalong with their sister GLP-1s for diabetes, Mounjaro and Ozempic, respectivelyto its list of drugs in shortage, opening the door for compounding pharmacies to legally produce compounded versions for patients who were not able to source branded products
doi: 10.1161/CIRCULATIONAHA.125.074545 Summary Keywords cardiovascular outcomes, SGLT2 inhibitors, GLP-1 agonists, combination therapy, heart failure, renal outcomes Citation Aristizbal-Colorado D, Corredor-Rengifo D, Sierra-Castillo S, Lpez-Corredor C, Vernaza-Trujillo D-A, Weir-Restrepo D, Izquierdo-Condoy JS, Ortiz-Prado E, Rico-Fontalvo J, Gmez-Mesa J-E, Abreu-Lomba A and Rivera-Martnez W-A (2025) A decade of progress in type 2 diabetes and cardiovascular disease: advances in SGLT2 inhibitors and GLP-1 receptor agonists a comprehensive review
Luo XJ, Li M, Huang L, Steinberg S, Mattheisen M, Liang G, et al
Her doctor prescribed an anti-nausea medication just in case, and she notes there are not many options. Wharton believes these medicines empower people to make healthy lifestyle changes but, just as with any other chronic conditions of the mind or body, people experiencing health problems related to obesity will likely always require some form of treatment
IV glutathione, when medically supervised, generally shows faster and more consistent results due to higher bioavailability
Carnitine (3-hydroxy-4-N, N, N-trimethylaminobutyric acid) represents a comprehensive approach to muscle wellness through enhanced energy metabolism
.png)
